Chatenoud, Lucienne

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine

Diabetes and associated disordersDiabetes Management and Research

Cited by 1,099

Teplizumab and β-cell function in newly diagnosed type 1 diabetes

Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine

Diabetes and associated disordersDiabetes Management and Research

Cited by 273

Islet Autoantibody Standardization Program 2018 workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance

Lampasona, V., Pittman, D. L., Williams, A. J., Achenbach, P., Schlosser, M., Akolkar, B., Winter, W. E., Laboratories, P., Watson, K., Weets, I., et al. (2019) · Clinical Chemistry

Diabetes and associated disordersClinical Laboratory Practices and Quality Control

Cited by 103

Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials

Staeva, T. P., Chatenoud, L., Insel, R., & Atkinson, M. A. (2013) · Diabetes

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 91

A historical view from thirty eventful years of immunotherapy in autoimmune diabetes

Bach, J.-F., & Chatenoud, L. (2011) · Seminars in Immunology

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 41